All In Biotech

Drug Trial Radar · NCT01124552

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Last checked: Nov 19, 2026Latest source record: Jan 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Apr 2010

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

  • RT001 Botulinum toxin type A (Dose A)Drug

    RT001 Botulinum Toxin Type A (Dose A)

  • RT001 Botulinum Toxin Type A (Dose B)Drug

    RT001 Botulinum Toxin Type A (Dose B)

  • VehicleOther

    Vehicle Control

  • PlaceboDrug

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject improvement based in investigator assessmentTime frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Research Institute, LLC

    Coral Gables, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.